Nephroprotective Effects Of Sildenafil Against Nephrotoxicity In Animal Model
Abstract
Background: The nephroprotective drugs are having essential roles in reducing or preventing the possibility of toxicity with wide range of drugs used for severe infections or cancers and still now the researchers investigate many drugs with different mechanisms and examine their possibility to combined with nephrotoxic drugs in different ways in order to reduce their toxicity or prolong the limited duration of treatment. In same way, the present study designed to find the potential nephroprotective activity of sildenafil in reversing or reducing the nephropathies induced by gentamycin. Methods: The experiment was designed to include thirty-two rats and these were divided into four groups. The first ( control ) group received isotonic saline (2mL/kg/day i.p.). Second (positive control ) group were received only sildenafil (5 mg/kg/day orally p.o).Third (induction ) group received gentamycin (100 mg/kg/day i.p.). Fourth (treatment) group received sildenafil (5mg/kg/day p.o.) followed by gentamycin (100 mg/kg/day i.p.). The course of treatment continued to ten consecutive days . All animal were anesthsized at day 11th. and blood collected by special tubes by cardiac puncture in order to be used for investigating of serum creatinine, urea, total protein , albumin and kidney injury molecules-1(KIM-1). Also, the kidneys were harvested and kept in formalaldehyde 10% for evaluation of histopathological changes. Results: The gentamycin (induction)group showed all features of…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.